The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of PROLIA ® (denosumab) and XGEVA ® (denosumab) respectively [1], [2] STOBOCLO and OSENVELT, among ...

Guidelines recommend minimizing glucocorticoid exposure in patients with lupus (SLE), and research suggests this advice should also apply to those with lupus nephritis.

Cite this: Edited by Shreyasi Asthana. Glucocorticoid Dose Guides Safe Discontinuation of Pneumocystis Pneumonia Prophylaxis in Rheumatic Disease - Medscape - April 09, 2025.

In the 15-year risk analysis of prenatal exposure to systemic glucocorticoids, there was an increased risk of mental disorders, like ADHD.

This study evaluated crinecerfont’s efficacy in lowering androstenedione levels and reducing the need for high-dose glucocorticoids. The results indicated that crinecerfont treatment was superior to ...

In people withdrawing from exogenous glucocorticoids below the physiological equivalent dose, see the section on managing glucocorticoid withdrawal to prevent adrenal insufficiency.

Glucocorticoids are a mainstay of treatment for systemic lupus erythematosus (SLE). But due to long-term adverse effects, dose reduction is becoming a crucial part of treat-to-target management goals.

New evidence around use and thresholds in SLE — Glucocorticoids are a mainstay of treatment for systemic lupus erythematosus (SLE). But due to long-term adverse effects, dose reduction is ...

Glucocorticoid excess was common among patients with classic 21-hydroxylase deficiency prior to treatment with crinecerfont.

Glucocorticoid tapering, education and treatment of adrenal crisis are three of the main focuses of a new clinical practice guideline on glucocorticoid-induced adrenal insufficiency.